Beech Biotech is developing a novel treatment for preeclampsia, an severe unmet medical need that takes the lives of 70,000 women and 500,000 babies each year. The company is developing a novel placenta-impermeable antibody and works with a network of expert industry consultants and contractors.
Products, services, technology
The limitations on drug development through concerns for the safety of the foetus is solved by the design of antibodies which cannot cross the placenta, and thus only treat the mother. These 'mother-only' antibodies provide a new and unique platform for treating diseases and conditions of pregnancy.
Cooperation possibilities
Beech Biotech is outsourcing all activities to support drug development, including drug manufacture, pre-clinical services and regulatory consulting.
- https://beech-biotech.com/
- Send an email
- Ian Cottingham
Some insights
No new medicines are available for preeclampsia for over 20 years and the only treatment is preterm delivery of the baby. Beech Biotech is developing a medicine with the aim of prolonging gestation to allow the mother to carry her child longer thus avoiding the consequences of premature birth.
Beech Biotech is determined to create new treatments for diseases of pregnancy to improve the health of mothers and their babies across the world.
